Loading
HKSEHealthcareBiotechnology
Latest quote
HK$1.96
−HK$0.06 · -2.97%
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Latest quote
HK$1.96
−HK$0.06 · -2.97%
Regular session · HKT · Market data may be delayed.
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Day range
Current HK$1.96
52-week range
Current HK$1.96
Regular session · HKT · Market data may be delayed.
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Day range
Current HK$1.96
52-week range
Current HK$1.96
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 276.31M CNY | 158.22M CNY | 173.86M CNY | 145.7M CNY | 30.8M CNY |
| Cost of goods sold | 157.4M CNY | 80.9M CNY | 85.64M CNY | 86.95M CNY | 21.75M CNY |
| Gross profit | 118.91M CNY | 77.32M CNY | 88.22M CNY | 58.76M CNY | 9.05M CNY |
| Research and development | 141.62M CNY | 282.99M CNY | 413.62M CNY | 407.82M CNY | 414.4M CNY |
| Selling, general, and administrative | 219M CNY | 145.16M CNY | 117.75M CNY | 370.64M CNY | 372.25M CNY |
| Operating expenses | 360.62M CNY | 536.6M CNY | 877.83M CNY | 914.64M CNY | 768.13M CNY |
| Interest income | 20.41M CNY | 28.43M CNY | 34.03M CNY | 16.54M CNY | 8.3M CNY |
| Interest expense | 11.14M CNY | 12.22M CNY | 12.42M CNY | 6.79M CNY | 2.69M CNY |
| Depreciation and amortization | 79.76M CNY | 77.46M CNY | 99.83M CNY | 87.07M CNY | 33.01M CNY |
| Operating income | −241.71M CNY | −459.28M CNY | −789.61M CNY | −855.88M CNY | −759.08M CNY |
| Net income | −540.92M CNY | −590.62M CNY | −768M CNY | −846.14M CNY | −702.33M CNY |
Company facts updated Sep 13, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
